In recent years, with the continuous changes in the pharmaceutical industry and the continuous improvement of pharmaceutical requirements, pharmaceutical companies are also improving the automation, informatization and data of pharmaceutical equipment and production lines
.
From the current point of view, in order to achieve continuous production, reduce manual errors, improve production efficiency, and reduce production costs, a large number of domestic pharmaceutical companies have begun to invest heavily in the construction of new production lines
.
On November 30, WuXi AppTec subsidiary HeyLife announced that it has officially started production of another new fully automated isolation sterile injection production line at its Wuxi formulation base
.
This is the second fully automated isolation sterile injection production line put into operation by Heqing Pharma this year, with an annual production capacity of 10 million injections, which means that the company continues to improve the capacity
of the aseptic injection platform.
It is worth noting that in order to continuously improve the capacity of the injection platform, Heqing will also open the first high-activity sterile injection production line
in Wuxi in 2023.
It is worth mentioning that its formulation base in Middletown, Delaware, is also expected to be officially put into operation in 2025, and the injection platform located at the base will provide integrated injection R&D and production services to global partners, further enhancing the ability
of the injection platform.
Winbond Health said on the investor interactive platform on November 30 that some production lines in the new factory of Hanjiang Pharmaceutical, the company's holding subsidiary, have completed production verification and are being arranged to put into production
gradually.
Its old factory area will not be used as the main production base in the future, and the company will use the existing business premises in the old factory area to carry out foreign investment promotion work
.
It is understood that Hanjiang Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceutical APIs and intermediates, covering steroidal hormones, insect repellent, respiratory system and digestive system products
.
On November 17, Erkang Pharmaceutical issued an announcement that it intends to self-raise 1 billion yuan to invest in the construction of lithium carbonate and its preparation projects
.
The lithium carbonate and its preparation project will complete the lithium carbonate and its preparation production line project, including the expansion of the preparation workshop and the new lithium carbonate raw material production workshop, and the construction period is expected to be 6 months
.
The expansion of the formulation plant will have an annual production capacity
of 47 million bags of powder and 5 billion tablets.
For this investment and construction, Erkang Pharmaceutical said that if the project is successfully completed, it will help enrich product varieties and create new profit growth points
.
In addition, as early as September 9, Fosun Pharma also announced that the new dry suspension production line of its holding subsidiary, Suzhou Erye, located in Xiangcheng District, Suzhou City, has passed the compliance inspection of good manufacturing practices (i.
e.
GMP compliance inspection).
The dry suspension production line has a design capacity of 6 million bottles per year, and the main product is oseltamivir phosphate dry suspension, which is mainly used for the treatment and prevention
of influenza A and B.
In general, in order to increase production capacity, enrich product varieties, improve platform capabilities and other reasons, pharmaceutical companies have become the norm in the industry to invest in the construction of new production lines
.
The industry expects that in the future, with the normalization of drug centralized procurement and the continuous promotion of medical insurance, these new production lines are expected to play a huge role
in accelerating production capacity and accelerating innovation for pharmaceutical companies.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
